Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.46 |
| ▸ | CHUK | O15111 | 11/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.43 |
| ▸ | NEK1 | Q96PY6 | 4/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13013344 | 0.89 | IKBKB (0.42) | IKBKBCHUKROCK1NEK1PTGDR2 | |
| SCHEMBL13014033 | 0.89 | IKBKB (0.56) | IKBKBCHUKROCK1NEK1PTGDR2 | |
| SCHEMBL3417470 | 0.87 | IKBKB (0.43) | IKBKBCHUKROCK1NEK1PTGDR2 | |
| SCHEMBL3415001 | 0.85 | IKBKB (0.43) | IKBKBCHUKROCK1NEK1PTGDR2 | |
| SCHEMBL3412830 | 0.81 | IKBKB (0.43) | IKBKBCHUKROCK1NEK1PTGDR2 | |
| SCHEMBL13013877 | 0.76 | IKBKB (0.40) | IKBKBCHUKROCK1NEK1PTGDR2 | |
| SCHEMBL13013982 | 0.76 | PTGDR2 (0.48) | PTGDR2L3MBTL1 | |
| SCHEMBL3412397 | 0.74 | PTGDR2 (0.47) | PTGDR2L3MBTL1 | |
| SCHEMBL13505139 | 0.74 | PTGDR2 (0.46) | PTGDR2L3MBTL1MEN1ALDH1A1KMT2A | |
| SCHEMBL3412885 | 0.73 | IKBKB (0.40) | IKBKBCHUKROCK1NEK1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069341-B1 | PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS | GLAXO GROUP LTD (GB) | 2010-12-29 | — | — | EP | disclosed |
| US-20100035917-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20080176891-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176891-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | IKBKB 4/4885CHUK 8/4885ROCK1 467/4885 |
| US-20100035917-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS | PLK2, PDXK, MAP4K2 | IKBKB 428/4885CHUK 300/4885ROCK1 550/4885 |
| US-20080146606-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | IKBKB 4/4885CHUK 8/4885ROCK1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.